Sign in
Stories
COVID-19 Impact on Immunocompromised Patients
Share
Advancements in Antibodies to Protect Im...
Biosimilar Breakthrough: Simlandi FDA Ap...
COVID-19 Diagnostics and Gene Therapy Re...
AI-Powered Antigen Research Partnership
Advancements in Medical Trials
BioNTech's mRNA Cancer Vaccine Progress
Overview
API
AstraZeneca's studies reveal the disproportionate impact of COVID-19 on immunocompromised patients, highlighting the need for prophylactic interventions and innovative treatments. Aerium Therapeutics is advancing next-generation antibodies to protect immunocompromised persons against COVID-19, while the federal government's narrow focus on mAbs underscores the need for broader innovation.
Ask a question
How can healthcare systems optimize immune protection for immunocompromised patients?
How can the federal government encourage broader innovation in anti-viral therapies for COVID-19?
What are the potential implications of next-generation antibodies on the treatment landscape for COVID-19?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jun 2023
Jul 2023
Aug 2023
Sep 2023
Oct 2023
Coverage